logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10595515 B1

PDFFull Text
Date of Patent:
Mar. 24, 2020

Filed:

Oct. 01, 2015

Animal models, cell lines and methods for screening hepatitis c virus vaccines

Applicant:

National Research Council of Canada, Ottawa, CA;

Inventors:

Kevin Young, Ottawa, CA;

Lakshmi Krishnan, Ottawa, CA;

Assignee:

NATIONAL RESEARCH COUNCIL OF CANADA, Ottawa, CA;

Attorney:

Gavrilovich, Dodd & Lindsey LLP

Primary Examiner:

Valarie E Bertoglio

Int. Cl.
CPC ...
C12N 5/02 (2006.01); C12N 5/00 (2006.01); A01K 67/027 (2006.01); C12N 15/85 (2006.01); A61K 39/12 (2006.01); C12N 5/09 (2010.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); C12Q 1/70 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0271 (2013.01); A61K 39/12 (2013.01); C12N 5/0693 (2013.01); C12N 7/00 (2013.01); C12N 15/85 (2013.01); C12N 15/86 (2013.01); A01K 2207/12 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); A01K 2267/0337 (2013.01); A01K 2267/0393 (2013.01); A61K 2039/523 (2013.01); A61K 2039/5256 (2013.01); C12N 2710/10343 (2013.01); C12N 2770/24222 (2013.01); C12N 2770/24234 (2013.01); C12N 2840/206 (2013.01); C12Q 1/707 (2013.01);
Abstract

Modified non-human mammalian hepatoma cell lines that express hepatitis C virus (HCV) antigens and which are capable of generating tumours in a syngeneic animal model are provided. The cell lines are generated by genomic integration of an expression construct that comprises one or more HCV antigen-encoding sequences under the control of a constitutive promoter. The expression construct further comprises a selectable marker and a reporter gene under the control of the same promoter. The cell lines are useful for testing prophylactic and therapeutic vaccines against HCV either in vitro or in vivo.

Find Patent Forward Citations

Loading…